Prevalence and phenotypic susceptibility to doravirine of the HIV-1 reverse transcriptase V106I polymorphism in B and non-B subtypes.
Federica GiammarinoAdolfo de SalazarIsabelle MaletLaura ViñuelaAna FuentesFrancesco SaladiniNiccolò BartoliniCharlotte CharpentierSidonie Lambert-NiclotGaetana SterrantinoMaria Grazia ColaoValeria MicheliAda BertoliLavinia FabeniElisa TeyssouRafael DelgadoIker Falces-RomeroAntonio AguileraPerpetua GomesDimitrios ParaskevisMaria M SantoroFrancesca Ceccherini-SilbersteinAnne-Genevieve MarcelinCristina MorenoMaurizio ZazziFederico GarciaPublished in: The Journal of infectious diseases (2024)
The prevalence of the HIV-1 RT-V106I polymorphism in MeditRes HIV consortium remains low, but significantly more prevalent in subtypes D and F. V106I minimally decreased the susceptibility to doravirine in SDMs and most clinical isolates. Reduced susceptibility seems to occur at increased frequency in subtype F1, however the clinical impact remains to be investigated.